Genomic Medicine in Alzheimer’s disease

Genomic medicine in Alzheimer's disease explores the role of genetic factors in the development and progression of the disease. Research has identified several genes linked to Alzheimer's, such as APOE4, which increases the risk, and APP, PSEN1, and PSEN2 genes, which are associated with early-onset forms of the disease. Advances in genomic technologies, including whole-genome sequencing and gene editing, are paving the way for personalized treatments and early diagnosis. By understanding genetic risk factors, genomic medicine holds promise for identifying individuals at risk, developing targeted therapies, and potentially preventing or slowing Alzheimer's disease progression.

    Related Conference of Genomic Medicine in Alzheimer’s disease

    April 23-24, 2026

    8th World Depression Congress

    Paris, France
    May 14-15, 2026

    9th World Conference on Neuroscience

    Rome, Italy
    June 22-23, 2026

    18th Global Neurologists Meeting on Neurology and Neurosurgery

    Amsterdam, Netherlands
    June 22-23, 2026

    7th World Congress on Sleep Disorders and Therapeutics

    Amsterdam, Netherlands
    June 22-23, 2026

    38th World Conference on Neurology

    Barcelona, Spain
    June 29-30, 2026

    39th European Neurology Congress

    London, UK
    June 29-30, 2026

    37th Conference on Clinical Neuroscience and Neurogenetics

    Aix-en-Provence, France
    July 20-21, 2026

    37th World Congress on Neurology and Neuroscience

    Amsterdam, Netherlands
    July 23-24, 2026

    14th International Conference on Cannabis & Medicinal Research

    Amsterdam, Netherlands
    July 23-24, 2026

    16th Global Alzheimers Summit

    Paris, France
    September 18-19, 2026

    21st Annual Congress on Neuroscience

    Dubai, UAE
    November 16-17, 2026

    8th World Brain Congress

    Tokyo, Japan

    Genomic Medicine in Alzheimer’s disease Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in